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LGD-4033, a selective androgen receptor modulator, and MK-677, a growth
demographics. However, limited data exist describing their effects on health- and
androgen-related biomarkers. The purpose of this case study was to determine
changes in body composition and biomarkers during and after continued coadministration of LGD-4033 and MK-677. We also aimed to examine muscular
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5 weeks. Blood and body composition metrics were obtained pre-, on- and post-
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cycle. One-repetition maximum leg and bench press, in addition to intramuscular
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androgens and androgen receptor content, were analysed on-cycle. We observed
pre- to on-cycle changes in body composition (body mass, +6.0%; total lean body
mass, +3.1%; trunk lean body mass, +6.6%; appendicular lean body mass, +4.3%;
total fat mass, +15.4%; trunk fat mass, +2.8%; and appendicular fat mass, +14.8%),
bone (bone mineral content, −3.60%; area, −1.1%; and bone mineral density, −2.1%),
serum lipid-associated biomarkers (cholesterol, +14.8%; triglycerides, +39.2%; lowdensity lipoprotein–cholesterol, +40.0%; and high-density lipoprotein–cholesterol,
−36.4%), liver-associated biomarkers (aspartate aminotransferase, +95.8%; and
alanine aminotransferase, +205.0%) and androgen-associated biomarkers (free
testosterone, −85.7%; total testosterone, −62.3%; and sex hormone-binding globulin,
−79.6%); however, all variables returned to pre-cycle values post-cycle, apart from
total fat mass, appendicular fat mass, bone area, total cholesterol and low-density
lipoprotein–cholesterol. Follicle-stimulating hormone was below clinical reference
values on- (1.2 IU/L) and post-cycle (1.3 IU/L). Intramuscular androgen receptor
(−44.6%), testosterone (+47.8%) and dihydrotestosterone (+34.4%), in addition to
one-repetition maximum leg press and bench press (+39.2 and +32.0%, respectively),
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were different in the case subject compared with non-users. These data demonstrate
that LGD-4033 and MK-677 increase several body composition parameters, whilst
negatively impacting bone and several serum biomarkers. Given the sparsity of data
in recreationally using demographics, further research is warranted to elucidate the
acute and chronic physiological effects of these anabolic agents.
KEYWORDS

androgen receptor, ergogenic aid, growth hormone secretagogue, ibutamoren, ligandrol, muscle
strength, performance-enhancing drug, selective androgen receptor modulator, testosterone

1

INTRODUCTION

not well understood. MK-677 (also known as ibutamoren) is an orally
active non-peptide mimic of GH-releasing peptide, which has shown

Selective androgen receptor modulators (SARMs) are a class of

promise as an anabolic and therapeutic agent (Murphy et al., 1998;

engineered anabolic compounds that bind differentially to the

Nass et al., 2008; Svensson et al., 1998); nevertheless, currently no

androgen receptor (AR) and alter receptor function (Christiansen

data exist supporting its safety and efficacy when co-administered with

et al., 2020; Machek, Cardaci et al., 2020; Solomon et al., 2019). They

SARMs.

are posited to exert potent anabolic effects in skeletal muscle and

Although several investigations (Adunsky et al., 2011; Chapman

bone (Bhasin & Jasuja, 2009; Narayanan et al., 2018), whilst lacking

et al., 1997; Dobs et al., 2013; Svensson et al., 1998; Yuan et al., 2021)

the undesired androgenic-related side effects (testicular atrophy, fluid

and comprehensive reviews (Advani et al., 2018; Bhasin & Jasuja, 2009;

retention, hypertension, gynecomastia, alopecia, decreased libido,

Christiansen et al., 2020; Machek, Cardaci et al., 2020; Narayanan et al.,

etc.) commonly associated with anabolic androgenic steroids (Davani-

2018; Sigalos & Pastuszak, 2018; Sinha et al., 2020; Solomon et al.,

Davari et al., 2019; Efimenko et al., 2021; Rahnema et al., 2014; van

2019) have illustrated SARM- and GHS-specific safety and efficacy

Amsterdam et al., 2010). This is primarily attributable to the tissue-

in clinical settings, there is a paucity of literature evaluating their

selective nature of these compounds along with their limited ability

implications in otherwise healthy individuals. Incidentally, SARM and

to cross-react with other steroid receptors, aromatize to estradiol

GHS co-administration in recreational athletes has recently grown in

or reduce to dihydrotestosterone. For this reason, SARMs continue

popularity, with the aim of enhancing aesthetics, athletic performance

to be investigated in several clinical conditions, including sarcopenia,

and muscular strength (Efimenko et al., 2021; Hilkens et al., 2021; Holt

cachexia and osteoporosis, in addition to other androgen-related

& Ho, 2019; Shimko et al., 2021). This phenomenon is of particular

conditions, including urinary incontinence and prostate cancer (Bhasin

concern because we are unaware of any data that examine the

& Jasuja, 2009; Kadekawa et al., 2020; Komrakova et al., 2020; Nyquist

co-administration of these compounds, either in general or at the

et al., 2021; Srinath & Dobs, 2014). LGD-4033 (also known as ligandrol)

relatively large doses commonly taken by recreational users (Van

is a highly selective non-steroidal SARM with relatively high binding

Wagoner et al., 2017).

affinity that has been investigated in multiple preclinical and clinical

The purpose of this case study is to report longitudinal changes

models (Basaria et al., 2013; Fragkaki et al., 2018). Recently, however,

in body composition and in circulating androgen- and health-related

recreational use of LGD-4033 and other SARMs has increased without

biomarkers in an individual chronically co-administering the SARM

evidence supporting their utility or safety (Efimenko et al., 2021;

LGD-4033 and the GHS MK-677, both during and 4 weeks after the

Hilkens et al., 2021; Machek, Cardaci et al., 2020; Shimko et al., 2021).

cessation of use. We also aimed to examine the muscular strength

Furthermore, these compounds are rarely taken in isolation or at

of this subject cross-sectionally, alongside skeletal muscle androgenic

previously studied clinical doses.

hormone and receptor concentrations compared with non-users.

In some recreational settings, growth hormone secretagogues
(GHSs), a class of compounds developed to stimulate the secretion
of growth hormone (GH), can be co-administered with SARMs to

2

METHODS

‘maximize’ anabolism (Sigalos & Pastuszak, 2018; Sinha et al., 2020).
Once released into the circulation, GH stimulates the release of insulin-

2.1

Subject

like growth factor 1 by the liver to induce anabolic signalling in peripheral tissues, notably skeletal muscle (Velloso, 2008). Additionally,

A resistance exercise-trained male (age, 25.3 years; height, 178 cm;

GH can activate the GH receptor and elicit diverse downstream intra-

and training age, 8.8 years) participated in this case report. The sub-

cellular signalling (Carter-Su et al., 2016; Velloso, 2008). Similar to

ject self-administered 10 mg of LGD-4033 and 15 mg of MK-677 daily

SARMs, GHSs are being investigated to treat a variety of muscle-

for 5 weeks. Comprehensive blood analyses and body composition

wasting conditions (Conte et al., 2017; Murphy et al., 1998; Sigalos

testing were performed before (pre-cycle), immediately after 5 weeks

& Pastuszak, 2018); however, their recreational safety and utility are

of continuous use (on-cycle) and 4 weeks after cessation (post-cycle)
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of LGD-4033 and MK-677 use. Excision of skeletal muscle tissue and
muscular strength testing were conducted cross-sectionally while the

New Findings

subject was on-cycle. For collection of body composition metrics and

∙ What is the main observation in this case?

biospecimens, the subject was instructed to report to the laboratory

Co-administration of LGD-4033 and MK-677

upon waking in a rested, fasted and euhydrated state after refraining

increased body mass, lean mass and fat mass,

from exercise for 48 h. Methods of sample collection were approved

while negatively impacting bone, serum lipids,

by the Institutional Review Board for Human Subjects at Baylor

liver enzymes, testosterone (total and free) and,

University, and informed consent was obtained from the participant.

probably, follicle-stimulating hormone.

All procedures in the study conformed to the ethical considerations of

∙ What insights does it reveal?

the Declaration of Helsinki.

Our

2.2

cross-sectional

data

imply

that

these

compounds might alter intramuscular androgenic

Body composition

hormone and receptor concentrations along with
Total body mass (BM; in kilograms) and height (in centimetres) were

promoting muscular strength, when compared with

determined on a dual-beam balance scale (Detecto, Bridgeview, IL,

previously published data from trained males.

USA). Total body water (TBW; in litres and as a percentage) was
assessed via bioelectrical impedance analysis (Tanita, Tokyo, Japan).
Bone mineral content (BMC; in kilograms) and density (BMD; in
grams per centimetre squared), bone area (in centimetres squared),
trunk/appendicular lean mass (in kilograms), trunk/appendicular fat

however, these hormones were assessed on- and post-cycle to infer
potential decrements in upstream hypothalamic–pituitary–gonadal
activity (Machek, Cardaci et al., 2020).

mass (in kilograms) and visceral adipose tissue area (in centimetres
squared) were determined using dual-energy X-ray absorptiometry
(DEXA) (Hologic Discovery Series W, Waltham, MA, USA). A four-

2.5

Skeletal muscle biopsy and tissue processing

compartment model was used to calculate total fat mass (FM; in
kilograms) and total lean body mass (LBM; in kilograms) using DEXA-

A single muscle sample was obtained in a fasted and rested state via

derived body volume (Smith-Ryan et al., 2017; Tinsley, 2018).

percutaneous muscle biopsies (total ∼30 mg) from the middle portion
of the vastus lateralis muscle of the dominant leg (midpoint between
the patella and greater trochanter) at a depth between 1 and 2 cm using

2.3

Muscular strength testing

a 14-gauge TRU-CORE 1 automatic biopsy instrument (Angiotech,
Medical Device Technologies, Gainesville, FL, USA) after subcutaneous

To determine muscular strength, the subject performed one-repetition

administration of local anaesthetic (1 ml of 1% lignocaine/xylocaine) as

maximum (1RM) tests for barbell bench press and 45◦ -angled leg

previously performed by our laboratory (Cardaci et al., 2021; Hwang

press (Nebula Fitness Equipement, Scottsdale, AZ, USA) as previously

et al., 2020; Machek, Hwang et al., 2020; Wilburn, Machek, Cardaci,

described by researchers in our laboratory (Cardaci et al., 2020) and in

Hwang et al., 2020, 2020). After removal, adipose tissue was trimmed

accordance with the National Strength and Conditioning Association

from the muscle specimens and they were immediately frozen and

(NSCA) guidelines (Haff & Triplett, 2015). The subject refrained from

stored at −80◦ C for later analysis. The muscle sample was weighed and

exercise for 48 h before testing. The 1RM was recorded as the

homogenized using a commercial tissue extraction reagent (Invitrogen

maximum weight that the participant was able to lift for one repetition

Corporation, Camarillo, CA, USA). Total muscle protein was isolated

for each exercise. A goniometer was used to establish 90◦ of knee

and supplemented with a protease inhibitor cocktail (Sigma Chemical

flexion on the leg press, and a marker placed corresponding to that

Company, St. Louis, MO, USA) with broad specificity for the inhibition

depth was used to enforce the full range of motion on each repetition.

of serine, cysteine and metalloproteases. Total muscle protein content
was analysed in duplicate and determined spectrophotometrically at

2.4

Venipuncture and blood analyses

a wavelength of 750 nm (Bio-Rad, Hercules, CA, USA) using bovine
serum albumin as the standard.

Antecubital venous blood samples were taken into 10 ml vacutainer
tubes using a 21-gauge phlebotomy needle. Comprehensive blood
analyses (complete blood count, metabolic, lipid, and androgen-

2.6
Intramuscular androgenic hormone and
receptor analyses

associated markers) were analysed by a Clinical Laboratory
Improvement Amendments-certified laboratory. Blood data were

Intramuscular total AR, testosterone and dihydrotestosterone

collected pre-cycle, on-cycle and post-cycle. All pre-cycle blood

concentrations were assessed using commercially available enzyme-

analyses were provided retrospectively. Follicle-stimulating hormone

linked immunosorbent assay (ELISA) kits (MyBioSource, San Diego,

(FSH) and luteinizing hormone (LH) were not assessed pre-cycle;

CA, USA; Eagle Biosciences, Nashua, NH, USA). The specificities
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(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

FIGURE 1
MK-677.

(l)

(m)

Anthropometric and body composition-associated parameters pre-, on- and post-cycle following co-administered LGD-4033 and

of total AR, testosterone and DHT ELISA kits were all 100%, with

post-cycle was observed in BM (−5.7%; Figure 1a), total LBM

the sensitivity estimated to be 0.1 ng/ml, 0.018 pg/ml and 6 pg/ml,

(−2.8%; Figure 1d), trunk LBM (−6.7%; Figure 1e), appendicular LBM

respectively. The sample was analysed in duplicate, and absorbances

(−2.9%; Figure 1f) and TBW (−2.1%; Figure 1b), while trunk FM

were determined at a wavelength of 450 nm using a microplate

increased further (+1.9%; Figure 1k) and total FM (−6.7%; Figure 1j)

reader (iMark, Bio-Rad, Hercules, CA, USA) against known standard

and appendicular FM (−1.0%; Figure 1l) decreased, albeit not to

curves. Final concentrations were expressed relative to total protein

pre-cycle levels. The BMC (−3.6%; Figure 1g), bone area (−1.1%;

concentration.

Figure 1h) and BMD (−2.1%; Figure 1i) decreased from pre- to oncycle. From on- to post-cycle, BMC (+3.02%; Figure 1g) and BMD
(+2.9%; Figure 1i) returned to near pre-cycle values, whereas bone

3

RESULTS

area (+0.1%; Figure 1h) did not. Visceral adipose tissue area increased
from pre- to on-cycle (+4.0%; Figure 1m) and increased further from

3.1

Body composition

on- to post-cycle (+13.6%; Figure 1m).

There was an increase from pre- to on-cycle in BM (+6.0%;
Figure 1a), total LBM (+3.1%; Figure 1d), trunk LBM (+6.6%;

3.2

Blood biomarkers

Figure 1e), appendicular LBM (+4.3%; Figure 1f), total FM (+15.4%;
Figure 1j), trunk FM (+2.8%; Figure 1k), appendicular FM (+14.8%;

Increases were observed from pre- to on-cycle in total cholesterol

Figure 1l) and TBW (+2.5%; Figure 1b). A decrease from on- to

(+14.8%; Table 1), triglycerides (+39.2%; Table 1) and low-density
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TA B L E 1

Pre-, on- and post-cycle comparison of comprehensive analysis of serum biomarker values

Units

White blood cells

×10 /µl

3.6–9.9

5.3

5.8

4.7

Red blood cells

×106 /µl

4.32–5.71

5.33

5.06

5.24

Hemoglobin

g/dl

13–16.6

15.4

14.9

14.9

Haematocrit

%
×103 /µl

Mean corpuscular volume

Pre-cycle

On-cycle

Post-cycle

40–49

47.9

44.4

46.1

158–384

167

234

157a

fl

76–98

90

87.7

88

Mean corpuscular haemoglobin

pg

26.7–33.2

28.9

29.4

28.4

Mean corpuscular haemoglobin
concentration

g/dl

32.3–36.1

32.2a

33.6

32.3

Red cell distribution width

%

12–14.8

13.4

13.1

12.3

Neutrophils

%

38–73

50.2

46.3

48

Lymphocytes

%

17–48

30.7

37.4

38.8

Monocytes

%

6.0–13.0

17b

13.4b

11.1

Eosinophils

%

1.0–8.0

1.3

2.4

1.5

Basophils

%

0–1

0.6

0.5

0.6

Fasting glucose

mg/dl

70–100

100

98

95

Blood urea nitrogen

mg/dl

9–25

15

17

24

Creatinine

mg/dl

0.67–1.17

1.14

1.05

1.26b

Sodium

mmol/L

136–145

140

138

139

Potassium

mmol/L

3.5–5.1

4.5

5.0

4.1

Chloride

mmol/L

100–109

101

99a

101

Carbon dioxide

mmol/L

21–32

28

27

28

Calcium

mg/dl

8.5–10.1

9.0

9.3

9.2

Total protein

g/dl

6.7–8.4

6.6a

6.7

6.9

Albumin

g/dl

3.4–5.0

4.6

4.2

4.4

Globulin

g/dl

1.9–3.7

2.0

2.5

2.5

Total bilirubin

mg/dl

0.20–1.0

0.4

0.3

0.5

Alkaline phosphatase

U/L

45–117

55

41a

58

24

47

b

25

b

29

U/L

0–35

Alanine aminotransferase

U/L

7–56

20

61

Glomerular filtration rate, calculated

ml/min/1.73 m2

>60

89

98

79

Total cholesterol

mg/dl

<200

155

178

177

Total triglyceride

mg/dl

<150

51

71

73

High-density lipoprotein–
cholesterol

mg/dl

>39

55

35

a

50

Low-density lipoprotein–cholesterol

mg/dl

<100

90

126b

111b

a

659

Total testosterone

b

3

Platelet count

Aspartate aminotransferase

a

Reference
range

Marker

ng/dl

250–827

639

241

Free testosterone

pg/ml

30.6–152.0

148

85.7

148.1

Sex hormone-binding globulin

nmol/L

14.55–94.64

29.9

6.1a

31.9

a

1.3a
5.4

Follicle-stimulating hormone

IU/L

1.5–12.4

Not assessed

1.2

Luteinizing hormone

IU/L

1.2–8.6

Not assessed

4.6

Lower than standard clinical reference range.
Higher than standard clinical reference range.
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(a)

(b)

(d)

(c)

(e)

F I G U R E 2 Cross-sectional comparison between the case subject and a previously described healthy, recreationally trained male population
with regard to intramuscular androgen targets and to leg and bench press strength metrics (Cardaci et al., 2020). Abbreviations: 1RM,
one-repetition maximum; NORM, values from the literature; SARM, values from the present subject. The ‘NORM’ values are shown as the
mean (±SEM).

lipoprotein–cholesterol (above reference value; +40.0%; Table 1) and

and bench press (Figure 2e) were notably greater (+39.2 and +32.0%,

remained elevated post-cycle. High-density lipoprotein–cholesterol

respectively) in the user compared with these previously published

decreased from pre- to on-cycle (below reference value; −36.4%;

data in non-users.

Table 1) and returned to near baseline values post-cycle. Aspartate
aminotransferase (+95.8%; Table 1) and alanine aminotransferase
displayed an increase from pre- to on-cycle (+95.8 and +205.0%,

4

DISCUSSION

respectively; both above reference value; Table 1), which subsequently
returned to near baseline post-cycle. A decrease in total testosterone

In this case report, we document the pattern of change in body

(below reference value; −62.3%; Table 1), free testosterone (−85.7%;

composition along with health- and androgen-related biomarkers in

Table 1) and sex hormone-binding globulin (SHBG; below reference

a resistance-trained male self-administering 10 mg of LGD-4033 and

value; −79.6%; Table 1) from pre- to on-cycle was observed, and

15 mg of MK-677 daily for 5 weeks. Additionally, these data are

all returned to near baseline values post-cycle. Follicle-stimulating

the first to cross-sectionally report the intramuscular androgenic

hormone was below reference values on- (1.2 IU/L; Table 1) and post-

hormone and receptor concentrations of an individual while ingesting

cycle (1.3 IU/L; Table 1), while LH was within the reference range. All

these compounds. Our data consequently indicate that LGD-4033

other metabolic, immune and haematological markers assessed did not

and MK-677 co-administration increased body mass, lean body

change notably over time (Table 1).

mass and fat mass while negatively impacting BMD, in addition
to serum lipids, liver enzymes, testosterone (total and free) and,
likely, FSH. Importantly, we also report minimal LGD-4033 and MK-

3.3
Muscular strength and intramuscular
androgenic hormone and receptor content

677 co-administration-mediated impacts on renal and haematological
markers. Moreover, the present cross-sectional data imply that these
anabolic agents ostensibly alter intramuscular androgen hormone and

In comparison to our previously published data in resistance-trained

receptor concentrations, along with promoting greater relative lower

non-users (Cardaci et al., 2020), intramuscular AR content was less

and upper body strength compared to previously published data on

(−44.6%; Figure 2a), whereas intramuscular testosterone (Figure 2c)

trained males (Cardaci et al., 2020).

and dihydrotestosterone (Figure 2b) were greater (+47.8 and +34.4%,

Although our data suggest that these compounds may increase body

respectively) in the case subject. Moreover, 1RM leg press (Figure 2d)

mass, muscle mass and muscular strength akin to anabolic-androgenic
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steroids (Andrews et al., 2018; Varanoske et al., 2022, 2020), the

previous data suggest that LGD-4033 (amidst the large propensity

negative effects on FM, bone, circulating blood lipids, liver enzymes

of existing SARM compounds) appears to increase skeletal muscle

and androgen-related markers should be strongly considered as

mass without commensurate improvements in muscular strength and

important contraindications (Albano et al., 2021; Andrews et al., 2018;

function. Conversely, our cross-sectional data imply that LGD-4033

Machek, Cardaci et al., 2020; Varanoske et al., 2020). Specifically, the

might support increases in muscle mass and strength, albeit this might

observed BMC, bone area and BMD decrements might potentially

be attributable to our subject co-administering MK-677 or consuming

be attributable to an LGD-4033-mediated decrease in circulating

a relatively larger (10-fold higher) LGD-4033 dose than those pre-

testosterone as an aromatizable substrate for estradiol conversion

viously administered in humans (Basaria et al., 2013). Furthermore,

(Machek, Cardaci et al., 2020). Although several alternative SARM

differences in training age between the case subject and previously

compounds demonstrate enhanced bone-associated parameters

published resistance-trained non-users (Cardaci et al., 2020) might

amidst impaired hypothalamic–pituitary–gonadal axis activity, the

explain, in part, the observed differences in muscular strength.

chronically high dose taken by the present case subject might have

In the absence of LGD-4033, MK-677 has been shown to increase

physiologically superseded any potential positive BMD augmentations

body mass, fat mass, muscle mass, bone mineral density, total body

(Furuya et al., 2012; Gao et al., 2005; Kearbey et al., 2007; Yin et al.,

water, appetite and to improve physical function (Adunsky et al., 2011;

2003). Furthermore, although a majority of the assessed serum

Nass et al., 2008; Svensson et al., 1998), primarily posited to be by

biomarkers in the present investigation returned to baseline post-

increasing circulating GH and insulin-like growth factor 1 (Chapman

cycle, FSH and low-density lipoprotein–cholesterol remained outside

et al., 1997). Although previous investigations have described MK-677-

clinical reference ranges. These persistent alterations might suggest

mediated decreases in serum low-density lipoprotein–cholesterol,

that pharmacological interventions are warranted as post-cycle

equivocal alterations in androgenic hormones and elevated blood

strategies to rescue hormonal and lipid homeostasis. Interestingly,

glucose, the present findings illustrate broad decrements in serum

fat mass also remained elevated 4 weeks post-cycle, whereas lean

lipids, suppressed androgenic targets and negligible changes in glucose

body mass returned to baseline. These data ultimately suggest a

(Chapman et al., 1997; Murphy et al., 1998; Nass et al., 2008; Sinha

potentially expedited return to an individual’s skeletal muscle mass

et al., 2020). Consequently, the discrepancy in the differential effects of

baseline relative to adipose tissue after cessation of compound

MK-677 on the aforementioned parameters is likely to be attributable

administration.

to co-administration with LGD-4033. It also remains possible that the

We also document a substantial reduction in serum total and free

elevations in both TBW and fat mass were mediated by MK-677, but

testosterone along with SHBG after 5 weeks of continued LGD-4033

it is ultimately difficult to parse out the impacts of each individual

and MK-677 use, demonstrating notable androgenic activity. Although

compound in the present study.

we also corroborate Basaria et al. (2013), amongst other SARMfocused investigations (Chen et al., 2005; Clark et al., 2017; Miller et al.,
2011; Neil et al., 2018), by demonstrating an LGD-4033-mediated

5

CONCLUSION

reduction in serum total and free testosterone and concomitant
SHBG, the present case study also presents a possibly novel impact

Recreational SARM and GHS use has grown as a popular method to

of LGD-4033 and MK-677 use on intramuscular androgens and

enhance aesthetics, muscular strength and/or athletic performance,

AR content. Although data are limited on this phenomenon, we

despite a lack of empirical support to substantiate their utility or

cautiously hypothesize that this might be a consequence of previously

safety in non-clinical demographics (Efimenko et al., 2021; Machek,

suggested ‘unique’ and/or ‘incomplete’ interactions or competitive

Cardaci et al., 2020). Furthermore, SARMs are rarely taken at pre-

binding between non-steroidal SARMs and the AR (Bhasin & Jasuja,

viously studied clinical doses and are commonly co-administered with

2009; Furuya et al., 2013; Machek, Cardaci et al., 2020; Ponnusamy

other pharmacological agents. Although this case report suggests

et al., 2017). Ostensibly, these interactions might alter intracellular

that LGD-4033 and MK-677 harness significant anabolic properties

androgenic hormone influx or AR transcriptional/translational activity.

and are likely to increase skeletal muscle mass and strength, our

While research is limited in humans, previous authors have

data also highlight a plethora of deleterious impacts on circulating

highlighted the potential deleterious effects of LGD-4033 and MK-677

metabolic, lipid and androgen-related markers. SARMs and GHS

use in humans for non-clinical contexts (Basaria et al., 2013; Flores

therein might erroneously be used as safer alternatives to anabolic-

et al., 2020; Koller et al., 2021; Machek, Cardaci et al., 2020; Nass

androgenic steroids and should be considered more thoughtfully for

et al., 2008). Similar to our present findings, increases in lean body

their contraindications (Albano et al., 2021; Machek, Cardaci et al.,

mass (Basaria et al., 2013), elevated liver enzymes (Basaria et al., 2013;

2020). Additionally, these are the first data to document intramuscular

Flores et al., 2020; Koller et al., 2021) and liver injury (Barbara et al.,

androgenic hormone and receptor content, and may be important to

2020; Flores et al., 2020; Koller et al., 2021), along with suppression

elucidate the anabolic and deleterious effects of these compounds in

of free and total testosterone, FSH, SHBG, high-density lipoprotein–

humans further. Future investigations are tasked with evaluating the

cholesterol and triglycerides have all been documented with LGD-

long-term effects of these and similar co-administrated compounds on

4033 use, demonstrating clear evidence of the androgenic activity

the physiology of recreational users, in addition to how any deleterious

of LGD-4033 (Basaria et al., 2013; Koller et al., 2021). Furthermore,

side effects can be optimally ameliorated.
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